(2022 SITC) Utilizing Neoadjuvant immunotherapy clinical trial design …
홍사덕
Journal Club
0
504
2023.01.28 11:20
Date: 2023.01.25
Topic 1 : Utilizing Neoadjuvant immunotherapy clinical trial design to move into earlier stages of disease and to obtain appropriate samples for laboratory studies
Topic 2: Molecular markers alteration after immunotherapy
Topic 3: Immunotherapy resistance & overcome strategy
<Conclusion>
Immune checkpoint therapy has joined the ranks of surgery, radiation and chemotherapy as a pillar of cancer treatment: combination strategies are the future.
Multiple immune checkpoints exist and are dynamic in their expression; therefore, they should be evaluated in both pre- and on-treatment human tumor samples to guide therapeutic decisions.
Pre-surgical and tissue-based clinical trials (Neoadjuvant therapy) provide a feasible platform for obtaining approval of therapy in earlier disease settings AND to study biologic effects in patients, which provide insights into mechanisms that can be targeted for rational combination therapies.
Tumors with acquired resistance exhibit an increase in hypoxic regions that are associated with decreased TILs and reduced MHC I
Topic 1 : Utilizing Neoadjuvant immunotherapy clinical trial design to move into earlier stages of disease and to obtain appropriate samples for laboratory studies
Topic 2: Molecular markers alteration after immunotherapy
Topic 3: Immunotherapy resistance & overcome strategy
<Conclusion>
Immune checkpoint therapy has joined the ranks of surgery, radiation and chemotherapy as a pillar of cancer treatment: combination strategies are the future.
Multiple immune checkpoints exist and are dynamic in their expression; therefore, they should be evaluated in both pre- and on-treatment human tumor samples to guide therapeutic decisions.
Pre-surgical and tissue-based clinical trials (Neoadjuvant therapy) provide a feasible platform for obtaining approval of therapy in earlier disease settings AND to study biologic effects in patients, which provide insights into mechanisms that can be targeted for rational combination therapies.
Tumors with acquired resistance exhibit an increase in hypoxic regions that are associated with decreased TILs and reduced MHC I
